The Christie School of Oncology: Christie Research Publications Repository
Not a member yet
16373 research outputs found
Sort by
Physician specialty shapes hypothetical self-treatment choices for locally advanced non-small cell lung cancer: is the 'best' option subjective?
No full textConventional Radiotherapy and Thoracic SABR for Synchronous Oligometastatic NSCLC: Acute Toxicity Findings from the SARON Thoracic Safety Sub-Study
No full textScreening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer
No full textThe anti-mitotic agent taxol (paclitaxel) remains a cornerstone of ovarian cancer treatment. To tackle drug resistance and toxicity, second-generation targeted anti-mitotic agents and combination strategies are being explored but have yet to demonstrate meaningful clinical benefits. A limitation is the lack of a platform to compare strategies in models that capture disease heterogeneity. To overcome this, we screen 83 patient-derived ex vivo ovarian cancer models that exhibit extensive intra- and inter-patient heterogeneity, testing four distinct approaches to enhance taxol sensitivity. Inhibitors of the HSET kinesin or the Mps1 spindle assembly checkpoint kinase show minimal impact on the taxol sensitivity landscape. By contrast, Bcl-xL inhibition exerts a global anti-proliferative effect. Inhibition of the MDR1 drug efflux pump restores taxol sensitivity in models characterized by ABCB1 overexpression. These MDR1-driven resistant models also respond to cabazitaxel, which is a poor MDR1 substrate, highlighting a potential therapeutic option for ovarian cancers with acquired taxol resistance
Trial in progress: QUINTESSENTIAL-2-a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide
No full textPRIMALung (EORTC-1901) preliminary data: PRophylactic cerebral irradiation (PCI) or active brain MRI surveillance in SCLC patients
No full textThe landscape of microbial associations in human cancer
No full textOncomicrobes are estimated to cause 15% of cancers worldwide. When cancer whole-genome sequencing (WGS) data are collected, the microbes present are also sequenced, allowing the investigation of potential etiological and clinical associations. Interrogating the microbial community for 8908 patients encompassing 22 cancer types from the Genomics England WGS dataset revealed that only colorectal tumors exhibited unmistakably distinct microbial communities that can reliably be used to distinguish anatomical site [positive predictive value (PPV) = 0.95]. This pattern was validated in two independent datasets. Potential clinical relevance uncovered by our analyses included accurate detection of alphapapillomaviruses [human papillomavirus (HPV)] in oral cancers, when compared with current clinical standards, and the detection of rare, highly pathogenic viruses such as human T-lymphotropic virus-1. Biomarker investigations demonstrated statistically significant associations (P < 0.05) between a subset of anaerobic bacteria and survival in certain subtypes of sarcoma. Our results contradict previous claims that each cancer type has a distinct microbiological signature but highlight the potential value of microbial analysis for certain cancers as WGS of tumor samples becomes common in the clinic
European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence
No full textEpendymomas are tumors of glial origin representing the second most common malignant brain tumors of childhood. Peak incidence in childhood is under 3 years of age. Most paediatric ependymomas arise intracranially and are molecularly divided into four groups, namely supratentorial ependymoma, ZFTA fusion-positive (ST-ZFTA), supratentorial ependymoma, YAP1 fusion-positive (ST-YAP1), posterior fossa group A (PF-A), and posterior fossa group B (PF-B) ependymoma. Spinal ependymomas in children are rare. An integrated diagnosis requires a combination of histological and molecular features as well as tumour localization. Staging with pre-and early post-surgery magnetic resonance imaging of the neuraxis, accompanied by cerebrospinal fluid (CSF) analysis 14 days post surgery must be performed. CSF at primary surgery is highly recommended to both detect and inform biomarkers. Patients should ideally be treated in specialized centers and, whenever possible, within a prospective clinical trial. Molecular classification has become increasingly important and will be applied to enable patient stratification in upcoming clinical trials. However, there are not yet specific treatment recommendations for distinct molecular groups. Apart from the molecular group, the extent of neurosurgical resection is the most consistent prognostic factor. Therefore, the feasibility of second-look surgery targeting complete resection should always be evaluated if residual disease. Adjuvant radiotherapy has been shown to be effective in consolidating local control and is therefore recommended following complete resection. Focal radiotherapy is the standard of care for patients with non-disseminated ependymoma, and craniospinal radiotherapy is recommended in older children with metastatic disease. For very young children with metastatic disease, radiotherapy avoidance strategies using systemic therapy is recommended to reduce the risk of neurocognitive effects. Highly conformal techniques such as proton beam therapy or intensity-modulated radiation therapy are preferred. Chemotherapy bridging therapy may be applied until patients reach 12-18 months of age, or to facilitate complete resections where further surgery is planned
UK real-world data of radium-223 dichloride in metastatic prostate cancer
No full textObjectivesTo evaluate the treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride in the UK.MethodsPatients initiating treatment with radium-223 from 1 September 2017 to 1 September 2019 in 15 UK oncology centres were included. Demographics, treatment, clinical, biochemical, and outcome data were collected prospectively. Quality of life data were obtained using analgesic scores and components of the Functional Assessment Cancer Therapy - Prostate (FACT-P) questionnaire.ResultsA total of 550 consecutive, evaluable patients were included. The most common prior therapy for mCRPC was enzalutamide. At final analysis, after a median follow-up of 13.3 months, 55% of patients had completed six cycles of treatment. Median overall survival was 13.7 months (95% confidence interval, 12.6-14.8 months). Poor performance status, prior use of docetaxel in the metastatic hormone sensitive prostate cancer (mHSPC) setting, number of lines of prior treatment, and abnormal platelet count were independent variables associated with poor prognosis. Adverse events led to treatment discontinuation in 5.5% of patients. WHO analgesic scores and FACT-P questionnaire scores did not significantly change after treatment administration.ConclusionThe National Radium-223 Dichloride Audit was the first and largest multicentre prospective analysis of treatment patterns, outcomes, and quality of life data in patients treated with radium-223 in the UK. Radium-223 can be administered safely to patients previously treated with other life-prolonging therapies. Efficacy and safety data compare favourably with clinical trial and other real-world data. Our results suggest that its use earlier in the treatment pathway is associated with longer survival
